| Biological Sciences | 2021-2025 | 438 | EG 4 | 99.53 |
| Chemistry | 2021-2025 | 156 | EG 1 | 99.22 |
| Medicinal and Pharmaceutical Chemistry | Lifetime | 90 | EG 2 | 95.32 |
| Molecular Biology | 2021-2025 | 173 | EG 1 | 99.32 |
| Medicinal and Pharmaceutical Chemistry | 2021-2025 | 4 | EG 1 | 98.25 |
| Organic Chemistry | 2021-2025 | 89 | EG 2 | 98.64 |
| Oncology | 2021-2025 | 552 | EG 2 | 92.06 |
| Computational Theory and Mathematics | 2021-2025 | 287 | EG 5 | 91.03 |
| Heterocyclic Compound Synthesis and Bioactivity | Lifetime | 88 | EG 3 | 99.04 |
| Synthesis and Biological Evaluation | Lifetime | 355 | EG 4 | 97.90 |
| Quinazolinone synthesis and applications | Lifetime | 111 | EG 4 | 96.91 |
| Synthesis and Characterization of Heterocyclic Compounds | Lifetime | 474 | EG 31 | 97.11 |
| Cancer therapeutics and mechanisms | Lifetime | 503 | EG 1 | 97.41 |
| Enzyme function and inhibition | Lifetime | 154 | EG 1 | 96.69 |
| Synthesis and Catalytic Reactions | Lifetime | 515 | EG 1 | 97.26 |
| Bioactive Compounds and Antitumor Agents | Lifetime | 451 | EG 3 | 95.53 |
| Cancer Mechanisms and Therapy | Lifetime | 439 | EG 1 | 95.58 |
| Phenothiazines and Benzothiazines Synthesis and Activities | Lifetime | 387 | EG 4 | 95.03 |
| Heterocyclic Compound Synthesis and Bioactivity | 2021-2025 | 14 | EG 6 | 99.52 |
| Cancer therapeutics and mechanisms | 2021-2025 | 13 | EG 3 | 98.80 |
| Cancer Mechanisms and Therapy | 2021-2025 | 16 | EG 2 | 98.08 |
| Quinazolinone synthesis and applications | 2021-2025 | 9 | EG 6 | 97.06 |
| Synthesis and Catalytic Reactions | 2021-2025 | 22 | EG 1 | 98.37 |
| Synthesis and Biological Evaluation | 2021-2025 | 34 | EG 12 | 97.18 |
| Enzyme function and inhibition | 2021-2025 | 7 | EG 1 | 98.62 |
| Bioactive Compounds and Antitumor Agents | 2021-2025 | 19 | EG 6 | 96.28 |
| Cancer-related Molecular Pathways | 2021-2025 | 41 | EG 1 | 96.55 |
| Synthesis and Characterization of Heterocyclic Compounds | 2021-2025 | 50 | EG 12 | 97.15 |
| Cholinesterase and Neurodegenerative Diseases | 2021-2025 | 60 | EG 2 | 95.50 |
| Computational Drug Discovery Methods | 2021-2025 | 345 | EG 7 | 95.62 |
| Phenothiazines and Benzothiazines Synthesis and Activities | 2021-2025 | 32 | EG 3 | 93.54 |
| Angiogenesis and VEGF in Cancer | 2021-2025 | 48 | EG 10 | 90.43 |
| Essential Oils and Antimicrobial Activity | 2021-2025 | 514 | EG 31 | 93.35 |
| Click Chemistry and Applications | 2021-2025 | 328 | EG 24 | 89.91 |
| Cytokine Signaling Pathways and Interactions | 2021-2025 | 210 | EG 6 | 84.98 |
| PI3K/AKT/mTOR signaling in cancer | 2021-2025 | 187 | EG 6 | 83.30 |
| Chemical Reactions and Mechanisms | 2021-2025 | 37 | EG 1 | 84.51 |
| Research on Leishmaniasis Studies | 2021-2025 | 949 | EG 5 | 75.64 |
| Phytochemistry and Bioactive Compounds | 2021-2025 | 562 | EG 18 | 35.23 |
